Kristen Spencer, DO, details the rationale of the phase 1/2 EVEREST-2 trial evaluating the novel CAR T product A2B694 in pancreatic cancer.
Kristen Spencer, DO
Advertisement
Kristen Spencer, DO, is an associate professor in the Department of Medicine at NYU Grossman School of Medicine and director of the Phase 1 Developmental Therapeutics Program at NYU Langone Perlmutter Cancer Center in New York.
Articles by Kristen Spencer, DO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5